ERBB2 and prostate carcinoma: The most widely targeted biomarkers in cancer therapy include HER2/neu for breast cancer patients and PSMA for prostate cancer patients (Advances in nano bio-robotics for cancer detection: Targeting 12 types of cancer cells, 2024).